An artificial intelligence (AI) medical technology and services company working inthe arena of real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers for risk assessment and disease surveillance, Eyenuk Inc. is structured around quickly and accurately identifying patients suffering from potentially blinding eye diseases and preserving their vision. Using computer vision and image analysis expertise, the company is developing a portfolio of products based on its proprietary retinal image analysis technology to identify and track the progression of eye diseases.Eyenuks first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of diabetic retinopathy. Eyenuk is on a mission to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimers disease
